Moderna Stock News

Moderna (MRNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the roa

Major U.S. equities indexes were mixed to open the trading week as stocks fluttered ahead of Tuesday's Consumer Price Inflation (CPI) report. After the previous CPI print revealed steeper-than-expecte

Moderna stock surged Monday, nearing its first breakout in over a year, after launching a third study of its cancer vaccine.

As an investor, you never really know how your investments will play out. Some companies that have been in long-term decline can suddenly become turnaround stocks and rise again, surprising everyone.

The global oncology ecosystem is at a pivotal juncture. Significant advancements in discovery, development, and delivery of novel cancer treatments are enhancing patient outcomes.

Healthcare stocks, especially biotech companies, are very risky for investors. Their share price can be highly volatile and surge higher or plummet lower based on news regarding a clinical trial, trea

ChatGPT stock predictions could be more than shots in the dark by AI. The processing and inferential power of artificial intelligence progresses seemingly exponentially every day.

Moderna's sales plunged in 2023 as demand for its COVID vaccine has been diminishing. The company has multiple products in its pipeline that could be key parts of its business in five years.

Lululemon is showing no signs of slowing down. Moderna and Roku are poised for a comeback.

Moderna is gaining on a rival in the coronavirus vaccine market. The biotech is nearing an important approval.

Eli Lilly could have the world's future best-selling drug in its lineup. Moderna is poised to expand beyond COVID with several new products potentially on the way.

Earnings season for the fourth quarter of calendar 2023 is coming to a close. Clear winners and losers are emerging from the reports.

CAMBRIDGE, MA / ACCESSWIRE / February 28, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced its participation in the following upcoming investor conferences: TD Cowen 44th Annual Healthcare Conferen

Moderna is trying to move on from its coronavirus vaccine heyday. Its respiratory syncytial virus (RSV) vaccine could launch this year.

CNBC's Jim Cramer explains why he is keeping an eye on shares of Moderna.